{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:07:08Z","timestamp":1789664828516,"version":"4.0.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1471-2377-14-65","type":"journal-article","created":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T09:03:29Z","timestamp":1396343009000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial"],"prefix":"10.1186","volume":"14","author":[{"given":"Alice","family":"Laroni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Brogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo Brescia","family":"Morra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonello","family":"Guidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Pozzilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Comi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Lugaresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Turrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora","family":"Raimondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Uccelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Luigi","family":"Mancardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,4,1]]},"reference":[{"key":"1006_CR1","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1056\/NEJMoa0907839","volume":"362","author":"JA Cohen","year":"2010","unstructured":"Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L, TRANSFORMS Study Group: Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010, 362: 402-415. 10.1056\/NEJMoa0907839.","journal-title":"N Engl J Med"},{"key":"1006_CR2","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa052643","volume":"355","author":"L Kappos","year":"2006","unstructured":"Kappos L, Antel J, Comi G, Montalban X, O\u2019Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW: Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006, 355: 1124-1140. 10.1056\/NEJMoa052643.","journal-title":"N Engl J Med"},{"key":"1006_CR3","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/NEJMoa0909494","volume":"362","author":"L Kappos","year":"2010","unstructured":"Kappos L, Radue EW, O\u2019Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P: A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010, 362: 387-401. 10.1056\/NEJMoa0909494.","journal-title":"N Engl J Med"},{"key":"1006_CR4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.pharmthera.2007.04.006","volume":"115","author":"V Brinkmann","year":"2007","unstructured":"Brinkmann V: Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther. 2007, 115: 84-105. 10.1016\/j.pharmthera.2007.04.006.","journal-title":"Pharmacol Ther"},{"key":"1006_CR5","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1681\/ASN.V1341073","volume":"13","author":"K Budde","year":"2002","unstructured":"Budde K, Schmouder RL, Brunkhorst R, Nashan B, L\u00fccker PW, Mayer T, Choudhury S, Skerjanec A, Kraus G, Neumayer HH: First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol. 2002, 13: 1073-1083.","journal-title":"J Am Soc Nephrol"},{"key":"1006_CR6","first-page":"117","volume":"18","author":"JP DiMarco","year":"2012","unstructured":"DiMarco JP, O\u2019Connor P, Cohen JA, Reder AT, Zhang-Auberson L, Tang D, Collins W, Kappos L: Fingolimod treatment initiation experience: cardiac and Holter electrocardiogram findings from three phase 3 studies. Multiple Sclerosis Journal. 2012, 18: 117-P530","journal-title":"Multiple Sclerosis Journal"},{"key":"1006_CR7","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1177\/1352458511410344","volume":"17","author":"PS Espinosa","year":"2011","unstructured":"Espinosa PS, Berger JR: Delayed fingolimod-associated asystole. Multiple Sclerosis Journal. 2011, 17: 1387-1389. 10.1177\/1352458511410344.","journal-title":"Multiple Sclerosis Journal"},{"key":"1006_CR8","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/s12012-012-9166-y","volume":"12","author":"G Cocco","year":"2012","unstructured":"Cocco G: A patient with Leiden V mutation, multiple sclerosis, psoriasis, and sicca syndrome: could celecoxib and fingolimod adversely affect the heart?. Cardiovasc Toxicol. 2012, 12: 266-272. 10.1007\/s12012-012-9166-y.","journal-title":"Cardiovasc Toxicol"},{"key":"1006_CR9","unstructured":"Questions and answers on the review of Gilenya. [http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Medicine_QA\/2012\/04\/WC500125689.pdf (accessed 12 April 2013)]"},{"key":"1006_CR10","unstructured":"FDA Drug Safety Communication: Revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Gilenya (fingolimod). [http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm303192.htm#data]"},{"key":"1006_CR11","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1177\/1352458511433302","volume":"18","author":"G Giovannoni","year":"2012","unstructured":"Giovannoni G, Southam E, Waubant E: Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence. Multiple Sclerosis Journal. 2012, 18: 932-946. 10.1177\/1352458511433302.","journal-title":"Multiple Sclerosis Journal"},{"key":"1006_CR12","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1212\/WNL.0b013e31820db40f","volume":"76","author":"R Hohlfeld","year":"2011","unstructured":"Hohlfeld R, Barkhof F, Polman C: Future clinical challenges in multiple sclerosis: Relevance to sphingosine 1-phosphate receptor modulator therapy. Neurology. 2011, 76: S28-S37. 10.1212\/WNL.0b013e31820db40f.","journal-title":"Neurology"},{"key":"1006_CR13","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1185\/03007995.2011.591370","volume":"27","author":"BMJ Uitdehaag","year":"2011","unstructured":"Uitdehaag BMJ, Barkhof F, Coyle PK, Gardner JD, Jeffery DR, Mikol DD: The changing face of multiple sclerosis clinical trial populations. Curr Med Res Opin. 2011, 27: 1529-1537. 10.1185\/03007995.2011.591370.","journal-title":"Curr Med Res Opin"},{"issue":"Meeting Abstrac","key":"1006_CR14","first-page":"P01.170","volume":"80","author":"B Hughes","year":"2013","unstructured":"Hughes B, Cascione M, McCague K, Pestreich L, Schofield L, Kim E, Barbato L: Cardiac effects of fingolimod after first dose administration and therapy change in patients with multiple sclerosis. Neurology. 2013, 80 (Meeting Abstracts 1): P01.170-","journal-title":"Neurology"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2377-14-65.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2377-14-65\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2377-14-65","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2377-14-65.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T03:39:23Z","timestamp":1630553963000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/1471-2377-14-65"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,1]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["1006"],"URL":"https:\/\/doi.org\/10.1186\/1471-2377-14-65","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,1]]},"assertion":[{"value":"23 December 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"65"}}